Ganga Pharmaceuticals Ltd (GANGAPHARM) — shareholding pattern, promoter holding, financials and share price
About Ganga Pharmaceuticals Ltd (GANGAPHARM)
Ganga Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GANGAPHARM and on the BSE under scrip code 539680. Its ISIN is INE615T01017.
Incorporated in 1989, Ganga Pharmaceuticals Ltd manufactures & trades in Pharmaceuticals & allied products (Ayurveda) [1]
Ganga Pharmaceuticals Ltd manufactures and trades ayurvedic pharmaceuticals, focusing on traditional medicine with a modern approach.
Established in 1994, the company took over an existing ayurvedic business in 1995, signifying a strong foundation in traditional medicine.
Listed peers in Pharmaceuticals: Unjha Formulations Ltd, Colinz Laboratories Ltd, Vivanza Biosciences Ltd, Decipher Labs Ltd, Brawn Biotech Ltd, Fabino Enterprises Ltd.
Valuation & Returns
At ₹12 a share, Ganga Pharmaceuticals Ltd (GANGAPHARM) was valued at a price-to-earnings ratio of 70.9x against an industry P/E of 36.41x and a price-to-book of 0.85x on a book value of ₹14.06 per share. Solomo computes return on equity of 1.22% and return on capital employed of 2.79% from filed results.
- P/E
- 70.9x
- Industry P/E
- 36.41x
- P/B
- 0.85x
- EPS (TTM)
- ₹0.12
- Book value / share
- ₹14.06
- ROE
- 1.22%
- ROCE
- 2.79%
- ROA
- 1.04%
- Debt / equity
- 0.13x
- Dividend yield
- 0%
- EBITDA margin
- 11.31%
- 52-week range
- ₹9.35 – ₹14.6
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2021In the year ended Mar 2021, Ganga Pharmaceuticals Ltd (GANGAPHARM) reported revenue of ₹2.37 crore, net profit of ₹0.02 crore and earnings per share of ₹0.05. That compares with revenue of ₹3.08 crore and net profit of ₹0.19 crore in Mar 2020. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹1.46 crore and net profit ₹0.08 crore (standalone).
| Metric | Mar 2020 | Mar 2021 |
|---|---|---|
| Revenue (₹ cr) | 3.08 | 2.37 |
| Net profit (₹ cr) | 0.19 | 0.02 |
| EPS (₹) | 0.47 | 0.05 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -0.26% | -3.05% | 1.95% | -3.65% |
| Profit growth | 5.53% | -15.98% | 27.77% | 60.00% |
| Stock price CAGR | 3% | 15% | 5% | -10% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 50.91% of Ganga Pharmaceuticals Ltd (GANGAPHARM). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2016.
Largest disclosed public shareholders in Mar 2026: BHAVESH DHIRAJLAL TANNA 6.61%, LENUS FINVEST PRIVATE LIMITED 6.34%, PLUTUS CAPITAL MANAGEMENT LLP 6.34%, PRAKASH DHIRAJLAL TANNA 5.5%, NIRANJAN KUMAR GOEL 2.44%, SANJAY DHANSUKHLAL SHAH 1.22%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 50.91% | - | - | - | 49.09% |
| Sep 2025 | 50.91% | - | - | - | 49.09% |
| Mar 2025 | 56.02% | - | - | - | 43.98% |
| Sep 2024 | 56.02% | - | - | - | 43.98% |
| Mar 2024 | 56.02% | - | - | - | 43.98% |
| Sep 2023 | 66.71% | - | - | - | 33.29% |
| Mar 2023 | 66.71% | - | - | - | 33.29% |
| Sep 2022 | 66.71% | - | - | - | 33.29% |